Butterfly Network reported preliminary, unaudited fourth quarter 2025 revenue growth of at least 17% year over year, driven by continued expansion of its handheld ultrasound business. President and CEO Joseph DeVivo highlighted strong momentum entering 2026, noting that robust demand for the Ultrasound-on-Chip™ platform and Intuitive software solutions underpins confidence in scaling the core commercial operation. DeVivo indicated that co-development and chip licensing opportunities will accelerate an inflection year in 2026, details of which he plans to outline at the upcoming J.P. Morgan Healthcare Conference.

Chief Financial Officer John Doherty stated that audited fourth quarter and full year 2025 results are expected in late February, at which time the company will also provide guidance for 2026. Doherty emphasized a disciplined approach to financial management, forecasting continued strong top-line growth while maintaining focus on cash flow and operating leverage as Butterfly scales its global commercial footprint.

On January 7, EVP and CFO John Doherty sold 60,182 shares in a transaction disclosed via an SEC filing, reducing his position by 4.65% to 1,234,688 shares. This insider sale adds to recent executive transactions and may attract investor scrutiny regarding near-term sentiment. Institutional ownership remains high at approximately 38%, with several funds having increased stakes in the fourth quarter, suggesting a potential stabilizing effect on liquidity.

Analyst coverage of Butterfly Network is mixed: three firms maintain Buy ratings, one holds, and one issues a Sell, with a consensus price target near $3.67. Technical indicators show recent strength off year-to-date lows, although the company remains unprofitable on a GAAP basis. Market participants are watching the planned 2026 “Beam Steering” API rollout, which could drive third-party app development and open new monetization avenues.